Publicações

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma

AuthID
P-00T-BPV

Author(s)

Bedke, J

Albiges, L

Capitanio, U

Giles, RH

Hora, M

Lam, TB

Ljungberg, B

Marconi, L

Klatte, T

Volpe, A

Abu Ghanem, Y

Dabestani, S

Fernandez Pello, S

Hofmann, F

Kuusk, T

Tahbaz, R

Powles, T

Bex, A

Tipo de Documento

Article

Year published

2021

Publicado

in EUROPEAN UROLOGY, ISSN: 0302-2838

Volume: 79, Número: 3, Páginas: 339-342 (4)

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1016/j.eururo.2020.12.005

Pubmed: 33357997

SCOPUS: 2-s2.0-85099364654

Wos: WOS:000694859600018

Source Identifiers

ISSN: 0302-2838

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma

Links Úteis

Ajuda